Group 1: Foreign Trade Performance - In 2025, Tianjin's total foreign trade import and export value reached 835.87 billion yuan, with exports exceeding 400 billion yuan for the first time, marking a year-on-year increase of 10.1% [1] - The export value of private enterprises in Tianjin reached 843.6 billion yuan, a year-on-year growth of 4.1%, with the number of exporting enterprises reaching a historical high of 11,400 [1] - The export of mechanical and electrical products was the largest category, totaling 871 billion yuan, accounting for over 60% of the city's total exports, with a year-on-year increase of 10.3% [1] Group 2: Cross-Border RMB Transactions - In 2025, Tianjin's cross-border RMB payment volume exceeded 630 billion yuan, a year-on-year increase of 17%, marking a historical high and achieving 3.5 times the scale of 2019 [11] - The volume of cross-border RMB business in Tianjin's goods trade grew by 24% year-on-year, accounting for over 30% of total foreign and domestic currency settlements [11] - The issuance of "Panda bonds" by overseas enterprises reached 6.8 billion yuan, with a year-on-year growth of 130% [11] Group 3: New Energy Industry Development - Tianjin's new energy industry is expected to achieve an output value of 80 billion yuan in 2025, with a year-on-year growth of 9.3% [5] - The city aims to build a comprehensive new energy industry chain, focusing on wind, solar, lithium, and hydrogen sectors [5] - The number of enterprises in Tianjin's new energy industry chain exceeds 110, contributing significantly to the high-quality development of the manufacturing sector [5] Group 4: Policy and Institutional Support - The People's Bank of China Tianjin Branch has established a special working group with ten government departments to enhance cross-border RMB transaction efficiency [11] - The implementation of cross-border RMB facilitation policies has expanded from three regions to sixteen, significantly increasing the number of recognized quality enterprises [12] - The total amount of cross-border RMB facilitation business in Tianjin has exceeded 540 billion yuan [12]

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak price of 2.88% and currently up by 2.52% [1] - Key performing stocks within the ETF include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1] - The market anticipates more international collaboration opportunities for Chinese innovative drug companies following the JPM Healthcare Conference held from January 12 to 15, 2026 [2][3] Group 2 - West Securities predicts that the Hong Kong innovative drug sector will continue to show structural trends in 2026, with accelerated BD (business development) overseas driving the convergence of drug price differences between China and the U.S. [3] - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [3] - The top ten weighted stocks in the Hang Seng Stock Connect Innovative Drug Select Index include Kangfang Biologics, CSPC Pharmaceutical Group, BeiGene, and China Biologic Products [3]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak of 2.88% and currently up by 2.52% [1][4]. Group 1: ETF Performance - The ETF's price reached a high of 0.577, with a current price of 0.569, reflecting a gain of 0.014 or 2.52% [2][6]. - The trading volume for the ETF was reported at 178,084 shares, with a turnover rate of 3.73% [6]. Group 2: Component Stocks - Notable performers among the ETF's component stocks include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1][5]. - Conversely, the stocks of Jiujiu Bio and Ascletis Pharma showed significant declines [1][5]. Group 3: Market Expectations - The JPM Healthcare Conference, held from January 12 to 15, 2026, has generated market anticipation regarding business development (BD) transaction data from Chinese innovative pharmaceutical companies, suggesting potential for increased international collaboration [6][7]. - The approval of updated labeling for the PD-1/VEGF dual antibody by the National Medical Products Administration for Kangfang Biopharma is expected to enhance treatment options for non-small cell lung cancer, indicating significant survival benefits [6][7]. Group 4: Industry Outlook - According to Western Securities, the innovative drug sector in Hong Kong is expected to maintain a structural market trend in 2026, with accelerated BD activities narrowing the price gap between Chinese and U.S. innovative drugs, leading to substantial long-term growth potential [7]. - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [7].

Core Viewpoint - The article highlights the urgent need for continued research and funding in the field of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, particularly in light of the deteriorating health of a prominent patient advocate, Cai Lei, who has been instrumental in raising awareness and funding for ALS research [3][4][5]. Group 1: Patient Advocacy and Research Efforts - Cai Lei, a former vice president of JD.com and ALS patient, has seen his health decline significantly, with his ALS Functional Rating Scale (ALSFRS-R) score dropping to single digits, indicating end-stage disease [3][10]. - Despite his deteriorating condition, Cai Lei has invested over 80 million yuan (approximately 11.2 million USD) in ALS research over the past two years, primarily funded through live-streaming income [5][13]. - His team has successfully facilitated clinical breakthroughs for 15 drug pipelines and treatment options, demonstrating the potential for collaborative research efforts in the ALS field [4][18]. Group 2: Funding and Research Challenges - The article discusses the challenges of funding in rare disease research, noting that commercial capital is often hesitant to invest in high-risk, early-stage clinical research [14]. - Cai Lei emphasizes the importance of philanthropic support, stating that charitable foundations and patient organizations are crucial for funding ALS research, as they do not seek short-term financial returns [14]. - The overall financing situation for rare diseases has improved, but significant challenges remain, particularly for projects that are not close to clinical application [14][18]. Group 3: Innovative Research Approaches - Cai Lei's team is building a global collaborative network of scientists, focusing on efficiency and support for researchers, rather than traditional research institutions [16][17]. - The team is leveraging advanced technologies, including AI and gene therapy, to explore new treatment avenues for ALS, with promising early results in animal models [22]. - Cai Lei advocates for a shift in focus towards breakthrough drug discovery, as current treatments have not effectively addressed the disease [21].

Core Viewpoint - The article highlights the ongoing struggle of a former executive, Cai Lei, who is battling ALS (Amyotrophic Lateral Sclerosis) while advocating for increased attention and funding for ALS research, emphasizing the need for sustainable scientific collaboration and commercial logic in rare disease research [1][3][4]. Group 1: Personal Experience and Advocacy - Cai Lei's health has deteriorated significantly, with his ALS functional rating score dropping from 48 to single digits, indicating he is in the terminal stage of the disease [1][5]. - He expresses concern that interest in ALS research may wane after his passing, similar to the decline in attention following the "Ice Bucket Challenge" in 2014 [3][4]. - Despite his condition, Cai Lei continues to advocate for ALS research, stating that he will fight until his last day [4][1]. Group 2: Research and Funding - Cai Lei's team has invested over 80 million yuan (approximately 11.2 million USD) in research over the past two years, primarily funded through live-streaming revenues [2][7]. - The team has successfully facilitated clinical breakthroughs for 15 drug pipelines and treatment plans, demonstrating a significant increase in research output and collaboration efficiency [2][11]. - Cai Lei emphasizes the importance of commercial logic in driving ALS research, noting that traditional funding sources are often hesitant to invest in high-risk, early-stage research [2][8]. Group 3: Collaborative Network and Research Efficiency - The team has established a global scientific collaboration network, involving hundreds of top scientists across various fields, to enhance research efficiency and support [9][10]. - This network operates as a "research accelerator," focusing on providing resources and support to scientists, thereby increasing the speed and effectiveness of research initiatives [9][10]. - The team aims to create a sustainable ecosystem for ALS research, prioritizing the needs of scientists and facilitating rapid project funding and execution [10][9]. Group 4: Future Directions and Technological Integration - Cai Lei advocates for the integration of advanced technologies, such as AI and gene therapy, to revolutionize ALS research and treatment [15][16]. - The team is working on developing an "ALS AI Research Brain," which aims to enhance research capabilities and identify potential therapeutic pathways for ALS [15][16]. - There is a call for more top scientists to engage in ALS research, focusing on breakthrough drug discovery and collaborative efforts to overcome key research bottlenecks [14][15].

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. announced that its subsidiary, Chengdu Hongji Biotechnology Co., Ltd., received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug KH631, which is intended for the treatment of Diabetic Macular Edema (DME) [1][4]. Group 1: Drug Information - The drug KH631 is an eye injection developed by Hongji Biotechnology, classified as a Class 1 therapeutic biological product [2]. - The drug has received clinical trial approval in China on November 15, 2022, and in the United States on November 22, 2022, for the treatment of Neovascular (Wet) Age-related Macular Degeneration (nAMD) [2]. - KH631 utilizes a proprietary Adeno-Associated Virus (AAV) delivery system, showcasing unique characteristics in tissue specificity, immunogenicity, controllable expression, and infection efficiency, with demonstrated sustained efficacy in preclinical disease models [2]. Group 2: Impact on the Company - The company acknowledges that the drug development process, including clinical trials, reviews, and approvals, carries inherent uncertainties, urging investors to make cautious decisions and be aware of investment risks [3].

Core Viewpoint - He Eye Hospital is advancing in the field of gene therapy, focusing on hereditary eye diseases and offering a range of services including genetic testing and personalized risk screening [2] Group 1: Gene Therapy Initiatives - He Eye Hospital, led by renowned expert Professor Pang Jijing, has established a specialized clinic for hereditary eye diseases [2] - The clinic provides services such as genetic testing, diagnosis, treatment, personalized risk screening, and health management for hereditary eye disease patients and their families [2] Group 2: Business Developments - The company is progressing with the acquisition of overseas Medial Corporation, which is involved in stem cell exosome research [2] - The business scope of the acquisition includes the development of anti-aging products [2] - Current developments have not significantly impacted the company's main business operations or performance [2]

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) announced that its subsidiary Chengdu Hongji Biotechnology Co., Ltd. received the Clinical Trial Approval Notice from the National Medical Products Administration for KH631 eye injection, aimed at treating Diabetic Macular Edema (DME) [1] Group 1 - KH631 eye injection is an innovative gene therapy product independently developed by Hongji Biotechnology, classified as a Class 1 therapeutic biological product [1] - The product received clinical trial approval from the National Medical Products Administration on November 15, 2022, and from the U.S. Food and Drug Administration on November 22, 2022, for conducting clinical trials for Neovascular (Wet) Age-related Macular Degeneration (nAMD) in the United States [1] - The product is based on a proprietary Adeno-Associated Virus (AAV) delivery system, featuring characteristics in tissue specificity, immunogenicity, controllable expression, and infection efficiency, demonstrating sustained efficacy in preclinical disease models [1]

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) announced that its subsidiary Chengdu Hongji Biotechnology Co., Ltd. received the Clinical Trial Approval Notice from the National Medical Products Administration for KH631 eye injection, aimed at treating Diabetic Macular Edema (DME) [1] Group 1 - KH631 eye injection is an innovative gene therapy product independently developed by Hongji Biotechnology, classified as a Class 1 biological product for treatment [1] - The product received clinical trial approval from the National Medical Products Administration on November 15, 2022, and from the U.S. Food and Drug Administration on November 22, 2022, for conducting clinical trials on Neovascular (Wet) Age-related Macular Degeneration (nAMD) in the United States [1] - KH631 is based on a proprietary Adeno-Associated Virus (AAV) delivery system, featuring characteristics in tissue specificity, immunogenicity, expression controllability, and infection efficiency, demonstrating sustained efficacy in preclinical disease models [1]

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) announced that its subsidiary Chengdu Hongji Biotechnology Co., Ltd. received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug KH631, an eye injection for the treatment of diabetic macular edema (DME) [1] Group 1: Drug Information - Drug Name: KH631 Eye Injection [1] - Dosage Form: Injection [1] - Indication: Treatment of Diabetic Macular Edema (DME) [1] - Registration Classification: Class 1 therapeutic biological product [1] - Acceptance Numbers: CXSL2500874, CXSL2500875 [1] - Approval Conclusion: Authorized to conduct clinical trials for the treatment of DME [1] Group 2: Product Development - KH631 Eye Injection is an innovative gene therapy product independently developed by Hongji Biotechnology [1] - The product received clinical trial approval from the China National Medical Products Administration on November 15, 2022, and from the U.S. Food and Drug Administration on November 22, 2022, for conducting clinical trials in the U.S. for neovascular (wet) age-related macular degeneration (nAMD) [1] - The product is based on an adeno-associated virus (AAV) delivery system with unique features in tissue specificity, immunogenicity, expression controllability, and infection efficiency, showing sustained efficacy in preclinical disease models [1]